XOMA Announces Transformational License Agreements for Gevokizumab and its IL-1 Beta Intellectual Property Portfolio Aug 25, 2017 7:00am EDT
XOMA to Present New Growth Strategy at the 2017 Wedbush PacGrow Healthcare Conference Aug 09, 2017 4:30pm EDT
XOMA Earns $10 Million Milestone Payment as Another of its Licensed Assets Advances into Clinical Development May 18, 2017 7:00am EDT
XOMA to Present New Strategic Initiatives at the UBS Global Healthcare Conference May 15, 2017 4:05pm EDT
XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition Apr 24, 2017 7:00am EDT
XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting Mar 28, 2017 7:00am EDT
